RARB and neoplasm: Importantly, reactivation of RARβ-dependent signaling that is inhibited by overexpression of GSK-3β returns profoundly unexpected sorafenib treatment outcome (tumor inhibition raised sharply from 48.3% to 93.4%) (Fig. 7A).